What the evidence supports
The literature supports biological activity in skin and repair models and identifies copper metabolism as a meaningful caution. It does not validate a standardized blood panel for GHK-Cu exposure.
Important distinction
A blood test cannot verify that a research vial contains the stated compound or is sterile. Product verification and clinical evaluation are separate questions.
What this evidence review covers
Explain that no validated GHK-Cu monitoring panel exists and avoid converting copper physiology into a self-testing protocol.
- Research endpoints versus clinical monitoring
- Why copper status is individualized
- No five-lab checklist
- When evidence is unknown
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
evidence gap
The audited core studies are cell/animal experiments and do not validate human monitoring.
regulatory
FDA describes limited human injectable safety data.
| Evidence class | What the source supports |
|---|---|
| evidence gap | The audited core studies are cell/animal experiments and do not validate human monitoring. |
| regulatory | FDA describes limited human injectable safety data. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
GHK-Cu stimulation of collagen synthesis in fibroblast culture
Evidence class: primary in vitro. What it supports: Collagen synthesis under defined cell-culture conditions.
What it does not establish: Clinical skin, hair, wound, or injectable outcomes.
GHK-Cu connective-tissue accumulation in rat experimental wounds
Evidence class: primary animal. What it supports: Extracellular-matrix findings in a rat wound model.
What it does not establish: Human treatment outcomes or injectable dosing.
Topical GHK-Cu in an irradiated rat wound model
Evidence class: primary animal. What it supports: A controlled preclinical result that did not improve the reported main vascular/ischemia outcomes.
What it does not establish: A general conclusion that GHK-Cu never works in any model or formulation.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
Should copper or ceruloplasmin be checked?
The packet does not establish a GHK-Cu-specific protocol or targets; that is an individualized clinical question.
Which biomarkers prove GHK-Cu works?
No validated clinical efficacy biomarker panel was identified.
What remains unresolved
- No validated monitoring panel.
- No target ranges or cadence.
- No human efficacy biomarkers established.